KRAS and cancer: In addition, Pietrasz et al20 reported that patients with ctDNA detectable by at least one cancer‐specific gene mutation, such as KRAS, TP53, and SMAD4, in the plasma collected after curative surgery had a significantly worse prognosis and shorter disease‐free survival than those with undetectable ctDNA.